medicaldevice-network.com
FDA fast tracks Bracco's BR55 for Crohn's disease bowel inflammation detection
A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response without radiation.
This is development-stage news—it signals potential future options rather than an available test.
Patients with Crohn’s disease and caregivers; gastroenterologists and radiologists; clinical researchers and industry observers.
What To Know
What to know The FDA has granted fast track designation to Bracco Imaging’s ultrasound molecular contrast agent BR55 for detecting active bowel inflammation in Crohn’s disease.
BR55 is a microbubble agent that targets VEGFR2 to boost ultrasound signal and has completed Phase II studies; the company is preparing Phase III trials to test efficacy and safety for identifying angiogenesis and active inflammation. BR55 is being developed as a non-invasive, radiation-free way to image disease activity and monitor treatment response.
Fast track status means the FDA sees this as addressing an unmet need and may allow expedited development and review, but it is not an approval and more evidence from Phase III trials will be needed. This article reports regulatory and development-stage news from a medical device industry outlet.
It summarizes prior Phase II findings and company statements; it does not provide clinical guidance, specific trial results, or changes to standard care.
Who should pay attention Patients with Crohn’s disease and their caregivers interested in new imaging options; gastroenterologists and radiologists who monitor IBD activity; clinical researchers and industry watchers following imaging biomarker development. More context Fast track designation can speed development and review but does not guarantee approval.
The article is industry-focused and cites completed Phase II work and planned Phase III trials; details on trial design, patient populations, and clinical performance in Crohn’s disease are not provided here. Readers should watch for peer-reviewed trial results and regulatory updates for clinical implications.
Fast track designation facilitates development and review but is not approval. The article summarizes company statements and Phase II findings; Phase III results and regulatory decisions will determine clinical use. No trial details or clinical performance metrics in Crohn’s are reported here.
